Skip to content
Screener

Exelixis EXEL Operating Income

Operating Income at other companies

Kura Oncology logo
Kura OncologyKURA
-$78.82M-21.8%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$96M-1,100%
Opko Health logo
Opko HealthOPK
-$6.97M+88.4%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$336.6M+702%
Incyte logo
IncyteINCY
$697.9M+31.6%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development211,987200,356411,903412,589
Selling, general and administrative147,632134,859287,234272,042
Total operating expenses380,276354,685739,747723,273
Income from operations248,414213,576499,755400,435
Interest income14,21016,78930,33735,865
Other income (expenses), net5450273(195)
Income before income taxes262,678230,415530,365436,105
Provision for income taxes50,62845,567107,84891,641

Item 1. Financial Statements.

FAQ

What is Exelixis's operating income?
Exelixis (EXEL) reported operating income of $248.41M in Q2 2026.
How has Exelixis's operating income changed year-over-year?
Exelixis's operating income increased by 16.3% year-over-year, from $213.58M to $248.41M.
What is the long-term trend for Exelixis's operating income?
Over 3 years (2021 to 2025), Exelixis's operating income has grown at a 44.9% compound annual growth rate (CAGR), from $286.67M to $872.19M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Exelixis's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude